

# Consolidated Financial Results for Fiscal 2017

(Reference Data of Financial Statements Fiscal 2017 1st Quarter)

August 1, 2017

**KAKEN PHARMACEUTICAL CO., LTD.**

Corporate Communications

Tel: +81-(0)3-5977-5002

Fax: +81-(0)3-5977-5131

Email: [koho@kaken.co.jp](mailto:koho@kaken.co.jp)

1. Summary of Consolidated Financial Statements for Fiscal 2017 1st Quarter

( Figures less than one million yen have been omitted)

	FY2016 1st Q	FY2016	FY2017 1st Q	Y o Y increase (decrease)		Plan FY2017	Y o Y increase (decrease)	
				Yen	%		Yen	%
Net sales	26,228	101,479	24,967	(1,260)	95.2%	101,700	221	100.2%
Operating income	8,097	30,707	7,649	(448)	94.5%	26,800	(3,907)	87.3%
Ratio of net sales	30.9%	30.3%	30.6%			26.4%		
Ordinary income	8,217	30,981	7,813	(403)	95.1%	27,000	(3,981)	87.1%
Ratio of net sales	31.3%	30.5%	31.3%			26.5%		
Net income	5,796	22,017	5,463	(333)	94.3%	19,100	(2,917)	86.8%
Ratio of net sales	22.1%	21.7%	21.9%			18.8%		
Comprehensive income	5,158	22,587	6,300	1,141	122.1%			
R&D expenses	1,899	6,450	1,836	(62)	96.7%	10,900	4,450	169.0%

2. Breakdown of Sales by Main Pharmaceuticals and Medical Devices

( Figures less than one million yen have been omitted)

	FY2016 1st Q	FY2016	FY2017 1st Q	%	Plan FY2017	%
Anti-osteoarthritis Artz	7,754	28,978	7,669	98.9%	29,700	102.5%
Anti-nail fungus Clenafin	5,796	21,624	5,741	99.0%	23,000	106.4%
Post-operative anti-adhesive Seprafilm	2,701	11,036	2,639	97.7%	11,200	101.5%
Anti-hyperlipidemia Lipidil	1,133	4,430	1,123	99.1%	4,600	103.8%
Wound healing agent Fiblast Spray	941	3,700	932	99.0%	3,800	102.7%
Generic products	3,045	11,903	3,011	98.9%	12,000	100.8%